HD-10991 / Hyundai Pharm - LARVOL DELTA

Combination therapy with selective SMARCA2 (BRM) inhibitor HD-11273 for treatment of SMARCA4 (BRG1)-deficient cancers (AACR 2026) - "We selected HD-11273 as a preclinical candidate, which showed improved physicochemical properties through the preparation of a specific salt of HD-10991, a selective SMARCA2 inhibitor...To evaluate the therapeutic benefit, we tested our selective SMARCA2 inhibitor in combination with KRASG12C (storasib, adagrasib), KRASG12D (RMC9805), and pan-KRAS (Draxonrasib) inhibitors in cancers harboring KRAS and SMARCA4 co-mutations...Additionally, we investigated the combinatory effect of a SMARCA2 inhibitor with standard chemotherapy agents for NSCLC; combination with oxaliplatin, docetaxel, or pemetrexed showed partial synergy, indicating that SMARCA2 inhibitors may serve as promising candidates for combination chemotherapy. In conclusion, the combination of HD-11273 with KRAS targeted therapy showed synergistic anti-tumor effect in preclinical models of SMARCA4 and KRAS co-mutated NSCLC. Also, the combination of HD-11273 with standard care for NSCLC chemotherapy significantly..."

Combination therapy • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • SMARCA2 • SMARCA4

Discovery of selective SMARCA2 inhibitors for the treatments of SMARCA4 mutated cancers (AACR 2025) - "Additional in vitro and in vivo studies in SMARCA4-mutant cell lines are ongoing to support the further development of these compounds. These findings, highlighting the anti-tumor efficacy and promising drug-like properties of HD-10991 and HD-11030, underscore their potential as candidates for preclinical studies aimed at therapeutic intervention for patients with SMARCA4-mutant cancers."

Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • SMARCA2 • SMARCA4